– CANADA, Montreal – Repare Therapeutics Inc. (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Dr. Susan Molineaux (Ph.D.) to its Board of Directors, effective at AGM in June 2023.
Concurrently, Dr. Jerel Davis will step down from the Board on that date.
“We are honored to welcome Dr. Molineaux to our Board. Her deep experience and accomplishments as an oncology drug developer will provide valuable guidance as Repare continues to advance and expand its clinical pipeline,” said CEO, Lloyd Segal.
About Dr. Susan Molineaux
Dr. Susan Molineaux currently serves as President and CEO of Para Therapeutics Inc., a position she has held since April 2023. Most recently, she served as President and CEO of Calithera Biosciences, Inc., which she co-founded in March 2010. Before Calithera, she was a co-founder of Proteolix, Inc., and served as CSO before becoming President and CEO until the Company’s acquisition by Onyx Pharmaceuticals, Inc. in November 2009. Previously, she held various senior scientific and management positions at Rigel Pharmaceuticals, Inc. and Merck & Co.
Dr. Molineaux is a member of the Boards of Directors of Geron Corp., Cyteir Therapeutics, Inc., and Smith College, and is a Scientific Advisor for Lightstone Ventures.
“I am thrilled to join the Board of Repare at such an exciting time in the Company’s growth and evolution,” said Dr. Susan Molineaux. “I look forward to collaborating with my fellow Board members and contributing to the executive team’s execution of its business plans and strategy to deliver synthetic lethal medicines that meaningfully improve the lives of cancer patients.”
Dr. Molineaux earned a B.S. in Biology from Smith College and a Ph.D. in Molecular Biology from Johns Hopkins University and completed a postdoctoral fellowship at Columbia University.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to discovering and developing novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and create highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development; camonsertib (also known as RP-3500 or RG6526), a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche; a preclinical Polθ inhibitor program; as well as several additional, undisclosed preclinical programs.
Source: https://www.reparerx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.